Cervical cancer is the second most common malignancy and the third reason for mortality among women in developing countries. Although infection by the oncogenic human papilloma viruses is a major cause, genomic contributors are still largely unknown. Network analyses, compared with candidate gene studies, offer greater promise to map the interactions among genomic loci contributing to cervical cancer risk. We report here a differential co-expression network analysis in five gene expression datasets (GSE7803, GSE9750, GSE39001, GSE52903, and GSE63514, from the Gene Expression Omnibus) in patients with cervical cancer and healthy controls. Kaplan-Meier Survival and principle component analyses were employed to evaluate prognostic and diagnostic performances of biomarker candidates, respectively. As a result, seven distinct co-expressed gene modules were identified. Among these, five modules (with sizes of 9–45 genes) presented high prognostic and diagnostic capabilities with hazard ratios of 2.28–11.3, and diagnostic odds ratios of 85.2–548.8. Moreover, these modules were associated with several key biological processes such as cell cycle regulation, keratinization, neutrophil degranulation, and the phospholipase D signaling pathway. In addition, transcription factors ETS1 and GATA2 were noted as common regulatory elements. These genomic biomarker candidates identified by differential co-expression network analysis offer new prospects for translational cancer research, not to mention personalized medicine to forecast cervical cancer susceptibility and prognosis. Looking into the future, we also suggest that the search for a molecular basis of common complex diseases should be complemented by differential co-expression analyses to obtain a systems-level understanding of disease phenotype variability.
Get full access to this article
View all access options for this article.
References
1.
AdamsAK, Wise-DraperTM, and WellsSI. (2014). Human papillomavirus induced transformation in cervical and head and neck cancers. Cancers (Basel), 15, 1793–1820.
2.
Aguirre-GamboaR, Gomez-RuedaH, Martínez-LedesmaE, et al. (2013). SurvExpress: An online biomarker validation tool and database for cancer gene expression data using survival analysis. PLoS One, 8, e74250.
ArbynM, CastellsaguéX, de SanjoséS, BruniL, SaraiyaM, BrayF, and FerlayJ. (2011). Worldwide burden of cervical cancer in 2008. Ann Oncol, 22, 2675–2686.
5.
ArnoukH, MerkleyMA, PodolskyRH, et al. (2009). Characterization of molecular markers indicative of cervical cancer progression. Proteomics Clin Appl, 3, 516–527.
6.
AssenovY, RamírezF, SchelhornSE, LengauerT, and AlbrechtM. (2008). Computing topological parameters of biological networks. Bioinformatics, 24, 282–284.
7.
BarrettT, WilhiteSE, LedouxP, et al. (2013). NCBI GEO: Archive for functional genomics data sets-update. Nucleic Acids Res, 41, 991–995.
8.
BodelonC, VinokurovaS, SampsonJN, et al. (2016). Chromosomal copy number alterations and HPV integration in cervical precancer and invasive cancer. Carcinogenesis, 37, 188–196.
9.
BolstadBM, IrizarryRA, AstrandM, and SpeedTP. (2003). A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics, 19, 185–193.
10.
BourgoRJ, BradenWA, WellsSI, and KnudsenES. (2009). Activation of the retinoblastoma tumor suppressor mediates cell cycle inhibition and cell death in specific cervical cancer cell lines. Mol Carcinog, 48, 45–55.
11.
BovolentaLA, AcencioML, and LemkeN. (2012). HTRIdb: An open-access database for experimentally verified human transcriptional regulation interactions. BMC Genomics, 13, 405.
12.
BurnsMB, TemizNA, and HarrisRS. (2013). Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet, 45, 977–983.
13.
CarterJR, DingZ, and RoseBR. (2011). HPV infection and cervical disease: A review. Aust N Z J Obstet Gynaecol, 51, 103–108.
14.
CicekAE. (2017). k-Shell decomposition reveals structural properties of the gene coexpression network for neurodevelopment. Turk J Biol, 41, 333–341.
15.
ChenH, WangD, and LiuY. (2016). SASH1 inhibits cervical cancer cell proliferation and invasion by suppressing the FAK pathway. Mol Med Rep, 13, 3613–3618.
16.
ChenY, WangH, LinW, and ShuaiP. (2017). ADAR1 overexpression is associated with cervical cancer progression and angiogenesis. Diagn Pathol, 12, [Epub ahead of print]; DOI: 10.1186/s13000-017-0600-0.
17.
ChengJ, LuX, WangJ, ZhangH, DuanP, and LiC. (2017). Interactome analysis of gene expression profiles of cervical cancer reveals dysregulated mitotic gene clusters. Am J Trans Res, 9, 3048–3059.
18.
ChouWC, ChengAL, BrottoM, and ChuangCY. (2014). Visual gene-network analysis reveals the cancer gene co-expression in human endometrial cancer. BMC Genomics, 15, 300.
19.
ClineMS, SmootM, and CeramiE. (2007). Integration of biological networks and gene expression data using Cytoscape. Nat Protoc, 2, 2366–2382.
20.
CollinM, DickinsonR, and BigleyV. (2015). Haematopoietic and immune defects associated with GATA2 mutation. Br J Haematol, 169, 173–187.
21.
DasariS, WudayagiriR, and ValluruL. (2015). Cervical cancer: Biomarkers for diagnosis and treatment. Clin Chim Acta, 445, 7–11.
22.
Den BoonJA, PyeonD, WangSS, et al. (2015). Molecular transitions from papillomavirus infection to cervical precancer and cancer: Role of stromal estrogen receptor signaling. Proc Natl Acad Sci USA, 112, 3255–3264.
23.
DengSP, ZhuL, and HuangDS. (2016). Predicting hub genes associated with cervical cancer through gene co-expression networks. IEEE/ACM Trans Comput Biol Bioinform, 13, 27–35.
24.
DeoPN, and DeshmukhR. (2018). Pathophysiology of keratinization. J Oral Maxillofac Pathol, 22, 86–91.
25.
DickFA, and RubinSM. (2013). Molecular mechanisms underlying RB protein function. Nat Rev Mol Cell Biol, 14, 297–306.
26.
EspinosaAM, AlfaroA, Roman-BasaureE, et al. (2013). Mitosis is a source of potential markers for screening and survival and therapeutic targets in cervical cancer. PLoS One, 8, e55975.
27.
EwaldDA, MalajianD, KruegerJG, et al. (2015). Meta-analysis derived atopic dermatitis (MADAD) transcriptome defines a robust AD signature highlighting the involvement of atherosclerosis and lipid metabolism pathways. BMC Med Genomics, 8, [Epub ahead of print]; DOI: 10.1186/s12920-015-0133-x.
28.
FangSQ, GaoM, XiongSL, ChenHY, HuSS, and CaiHB. (2018). Combining differential expression and differential coexpression analysis identifies optimal gene and gene set in cervical cancer. J Can Res Ther, 14, 201–207.
29.
FangY, and ZhangX. (2016). Targeting NEK2 as a promising therapeutic approach for cancer treatment. Cell Cycle, 15, 895–907.
30.
Fernandez-RetanaJ, Zamudio-MezaH, Rodriguez-MoralesM, et al. (2017).Gene signature based on degradome-related genes can predict distal metastasis in cervical cancer patients. Tumour Biol, 39, [Epub ahead of print]; DOI: 10.1177/1010428317711895.
31.
GautierL, CopeL, BolstadBM, and IrizarryRA. (2004). Affy- analysis of Affymetrix Gene Chip data at the probe level. Bioinformatics, 20, 307–315.
32.
GentlemanRC, CareyVJ, BatesDM, et al. (2004). Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol, 5, R80.
33.
GovE, and ArgaKY. (2016). Interactive cooperation and hierarchical operation of microRNA and transcription factor crosstalk in human transcriptional regulatory network. IET Syst Biol, 10, 219–228.
34.
GovE, and ArgaKY. (2017a). Differential co-expression analysis reveals a novel prognostic gene module in ovarian cancer. Sci Rep, 7, 4996.
35.
GovE, KoriM, and ArgaKY. (2017b). Multiomics analysis of tumor microenvironment reveals Gata2 and miRNA-123-3p as potential novel biomarkers in ovarian cancer. OMICS, 21, 603–615.
36.
Guardado-EstradaM, Medina-MartínezI, Juárez-TorresE, et al. (2012). The Amerindian mtDNA haplogroup B2 enhances the risk of HPV for cervical cancer: De-regulation of mitochondrial genes may be involved. J Hum Genet, 57, 269–276.
37.
GuoF, LiuY, LiY, and LiG. (2010). Inhibition of ADP-ribosylation factor-like 6 interacting protein 1 suppresses proliferation and reduces tumor cell invasion in CaSki human cervical cancer cells. Mol Biol Rep, 37, 3819–3825.
38.
GuoP, WangD, WuJ, et al. (2015). The landscape of alternative splicing in cervical squamous cell carcinoma. Onco Targets Ther, 8, 73–79.
39.
HolmesA, LameirasS, JeannotE, et al. (2016). Mechanistic signatures of HPV insertions in cervical carcinomas. NPJ Genom Med, 16, [Epub ahead of print]; DOI: 10.1038/npjgenmed.2016.4.
40.
HuangL, ZhengM, ZhouQM, et al. (2012). Identification of a 7-gene signature that predicts relapse and survival for early stage patients with cervical carcinoma. Med Oncol, 29, 2911–2918.
41.
KamburovA, StelzlU, LehrachH, and HerwigR. (2013). The ConsensusPathDB interaction database: 2013 update. Nucleic Acids Res, 41, 793–800.
42.
KanskaJ, ZakhourM, Taylor-HardingB, KarlanBY, and WiedemeyerWR. (2016). Cyclin E as a potential therapeutic target in high grade serous ovarian cancer. Gynecol Oncol, 143, 152–158.
43.
KlymenkoT, GuQ, HerbertI, et al. (2017). RNASeq analysis of differentiated keratinocytes reveals a massive response to late events during human papillomavirus type 16 infection, including loss of epithelial barrier function. J Virol [Epub ahead of print]; DOI: 10.1128/JVI.01001-17.
44.
KoriM, and ArgaKY. (2018). Potential biomarkers and therapeutic targets in cervical cancer: Insights from the meta-analysis of transcriptomics data within network biomedicine perspective. PLoS One, 13, e0200717.
45.
KumarS, ShahJP, BryantCS, et al. (2009). Prognostic significance of keratinization in squamous cell cancer of uterine cervix: A population based study. Arch Gynecol Obstet, 280, 25–32.
46.
LiJ, LiYX, and LiYY. (2016). Differential regulatory analysis based on coexpression network in cancer research. Biomed Res Int [Epub ahead of print]; DOI: 10.1155/2016/4241293.
47.
LinW, FengM, LiX, et al. (2017). Transcriptome profiling of cancer and normal tissues from cervical squamous cancer patients by deep sequencing. Mol Med Rep, 16, 2075–2088.
48.
LiuJ, ZhangJ, WangX, et al. (2010). HIF-1 and NDRG2 contribute to hypoxia-induced radioresistance of cervical cancer Hela cells. Exp Cell Res, 316, 1985–1993.
49.
LiuL, LeiJ, SandersSJ, et al. (2014). DAWN: A framework to identify autism genes and subnetworks using gene expression and genetics. Mol Autism, 5, 22.
50.
LiuMY, ZhangH, HuYJ, ChenYW, and ZhaoXN. (2016). Identification of key genes associated with cervical cancer by comprehensive analysis of transcriptome microarray and methylation microarray. Oncol Lett, 12, 473–478.
51.
LongNP, JungKH, YoonSJ, et al. (2017). Systematic assessment of cervical cancer initiation and progression uncovers genetic panels for deep learning-based early diagnosis and proposes novel diagnostic and prognostic biomarkers. Oncotarget, 8, 109436–109456.
52.
LópezJ, PoitevinA, Mendoza-MartínezV, Pérez-PlasenciaC, and García-CarrancáA. (2012). Cancer-initiating cells derived from established cervical cell lines exhibit stem-cell markers and increased radioresistance. BMC Cancer, 12, 48.
53.
LuoY, WuY, PengY, LiuX, BieJ, and LiS. (2016). Systematic analysis to identify a key role of CDK1 in mediating gene interaction networks in cervical cancer development. Iran J Med Sci, 185, 231–239.
54.
MaoY, FuA, LeadererD, ZhengT, ChenK, and ZhuY. (2013). Potential cancer-related role of circadian gene TIMELESS suggested by expression profiling and in vitro analyses. BMC Cancer, 13, 498.
55.
MedinaIR, and Lubovac-PilavZ. (2016). Gene co-expression network analysis for identifying modules and functionally enriched pathways in Type 1 Diabetes. PLoS One, 11, e0156006.
56.
Medina-MartinezI, BarrónV, Roman-BassaureE, et al. (2014). Impact of gene dosage on gene expression, biological processes and survival in cervical cancer: A genome-wide follow-up study. PLoS One, 9, e97842.
57.
MerschJ, JacksonMA, and ParkM. (2015). Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer, 121, 269–275.
58.
MiY, ZhangC, BuY, et al. (2015). DEPDC1 is a novel cell cycle related gene that regulates mitotic progression. BMB Rep, 48, 413–418.
59.
MiyatakeT, UedaY, NakashimaR, et al. (2007). Down-regulation of insulin-like growth factor binding protein-5 (IGFBP-5): Novel marker for cervical carcinogenesis. Int J Cancer, 120, 2068–2077.
60.
NoelJC, BucellaD, FaytI, et al. (2008). Androgen receptor expression in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix. Int J Gynecol Pathol, 27, 437–441.
61.
NyeMD, HoyoC, and HuangZ. (2013). Associations between methylation of paternally expressed gene 3 (PEG3), cervical intraepithelial neoplasia and invasive cervical cancer. PLoS One, 8, e56325.
62.
PappaKI, PolyzosA, Jacob-HirschJ, et al. (2015). Profiling of discrete gynecological cancers reveals novel transcriptional modules and common features shared by other cancer types and embryonic stem cells. PLoS One, 10, e0142229.
63.
Pérez de CastroI, de CárcerG, and MalumbresM. (2007). A census of mitotic cancer genes: New insights into tumor cell biology and cancer therapy. Carcinogenesis, 28, 899–912.
64.
PlotnikJP, BudkaJA, FerrisMW, and HollenhorstPC. (2014). ETS1 is a genome-wide effector of RAS/ERK signaling in epithelial cells. Nucleic Acids Res, 42, 11928–11940.
65.
PyeonD, NewtonMA, LambertPF, et al. (2007). Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. Cancer Res, 67, 4605–4619.
66.
RajkumarT, SabithaK, VijayalakshmiN, et al. (2011). Identification and validation of genes involved in cervical tumourigenesis. BMC Cancer, 11, 80.
67.
RostyC, ShefferM, TsafrirD, et al. (2005). Identification of a proliferation gene cluster associated with HPV E6/E7 expression level and viral DNA load in invasive cervical carcinoma. Oncogene, 24, 7094–7104.
68.
RoszakA, LianeriM, SowińskaA, and JagodzińskiPP. (2013). Involvement of PARP-1 Val762Ala polymorphism in the onset of cervical cancer in caucasian women. Mol Diagn Ther, 17, 239–245.
69.
SaitoR, SmootME, and OnoK. (2012). A travel guide to Cytoscape plugins. Nat Methods, 9, 1068–1076.
70.
SantinAD, ZhanF, and BignottiE. (2005). Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: Identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. Virology, 331, 269–291.
71.
ScottoL, NarayanG, NandulaSV, et al. (2008). Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: Potential role in progression. Genes Chromosomes Cancer, 47, 755–765.
72.
SeldersGS, FetzAE, RadicMZ, and BowlinGL. (2017). An overview of the role of neutrophils in innate immunity, inflammation and host-biomaterial integration. Regen Biomater, 4, 55–68.
73.
SevimogluT, and ArgaKY. (2015). Computational systems biology of psoriasis: Are we ready for the age of omics and systems biomarkers?. OMICS, 19, 669–687.
74.
SlebosRJ, YiY, ElyK, et al. (2006). Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res, 12, 701–709.
75.
SmythGK. (2005). LIMMA: Linear Models for Microarray Data. In: Bioinformatics and Computational Biology Solutions Using R and Bioconductor. GentlemanR, CareyVJ, HuberW, IrizarryRA, and DudoitS, eds. New York: Springer, pgs. 397–420.
76.
SpriggsCC, and LaiminsLA. (2017). FANCD2 binds human papillomavirus genomes and associates with a distinct set of DNA repair proteins to regulate viral replication. mBio, 8, e02340-16.
77.
SumanS, and SumanS. (2018). Network analysis revealed aurora kinase dysregulation in five gynecological types of cancer. Oncol Lett, 15, 1125–1132.
78.
The Cancer Genome Atlas Research Network. (2017). Integrated genomic and molecular characterization of cervical cancer. Nature, 543, 378–384.
79.
ThomasA, MahantshettyU, KannanS, et al. (2013). Expression profiling of cervical cancers in Indian women at different stages to identify gene signatures during progression of the disease. Cancer Med, 2, 836–848.
80.
TorreLA, BrayF, SiegelRL, FerlayJ, Lortet-TieulentJ, and JemalA. (2015). Global cancer statistics, 2012. CA Cancer J Clin, 65, 87–108.
81.
Van DamPA, van DamPJ, RolfoC, et al. (2016). In silico pathway analysis in cervical carcinoma reveals potential new targets for treatment. Oncotarget, 7, 2780–2795.
82.
Vazquez-OrtizG, Pina-SanchezP, VazquezK, et al. (2005). Overexpression of cathepsin F, matrix metalloproteinases 11 and 12 in cervical cancer. BMC Cancer, 5, 68.
83.
VerschoorML, WilsonLA, VerschoorCP, and SinghG. (2010). Ets-1 regulates energy metabolism in cancer cells. PLoS One, 5, e13565.
84.
VolgarevaGV, GolovinaDA, GasparjanNM, et al. (2007). STAT1 gene expression in cervical carcinomas. Biochemistry (Mosc), 72, 766–771.
85.
WangJ, SampathA, RaychaudhuriP, and BagchiS, (2001). Both Rb and E7 are regulated by the ubiquitin proteasome pathway in HPV-containing cervical tumor cells. Oncogene, 20, 4740–4749.
86.
WangSS, BrattiMC, RodríguezAC, et al. (2009). Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer. J Infect Dis, 199, 20–30.
87.
WillseyAJ, SandersSJ, LiM, et al. (2013). Coexpression networks implicate human midfetal deep cortical projection neurons in the pathogenesis of autism. Cell, 155, 997–1007.
88.
WolfDM, LenburgME, YauC, BoudreauA, and van't VeerLJ. (2014). Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity. PLoS One, 9, e88309.
89.
WongYF, CheungTH, TsaoGS, et al. (2006). Genome-wide gene expression profiling of cervical cancer in Hong Kong women by oligonucleotide microarray. Int J Cancer, 118, 2461–2469.
90.
WuFX, LiM, RuanJ, and LuoF. (2015). Systems biology approaches to mining high throughput biological data. Biomed Res Int, 2015, [Epub ahead of print]; DOI: 10.1155/2015/504362.
91.
WuS, LuS, TaoH, et al. (2011). Correlation of polymorphism of IL-8 and MMP-7 with occurrence and lymph node metastasis of early stage cervical cancer. J Huazhong Univ Sci Technol Med Sci, 31, 114–119.
92.
YangA, FarmerE, WuTC, and HunCF. (2016a). Perspectives for therapeutic HPV vaccine development. J Biomed Sci, 23, [Epub ahead of print]; DOI: 10.1186/s12929-016-0293-9.
93.
YangJ, ZhangZ, GuoW, et al. (2016b). Single nucleotide polymorphisms in microRNA genes are associated with cervical cancer susceptibility in a population from Xinjiang Uygur. Oncotarget, 7, 71447–71454.
94.
YinZ, SunY, GeS, and SunJ. (2017). Epigenetic activation of WHSC1 functions as an oncogene and is associated with poor prognosis in cervical cancer. Oncol Rep, 37, 2286–2294.
95.
YuX, WuK, HuangS, ZhangY, ZengT, and QiuY. (2016). Down-regulation of programmed cell death 4 (PDCD4) associates with the progression of cervical cancer. Int J Clin Exp Pathol, 9, 4424–4431.
96.
YuanL, ZhengCH, XiaJF, and HuangDS. (2015). Module based differential coexpression analysis method for type 2 diabetes. Biomed Res Int, 2015, [Epub ahead of print]; DOI: 10.1155/2015/836929.
97.
ZhaiY, KuickR, NanB, et al. (2007). Gene expression analysis of preinvasive and invasive cervical squamous cell carcinomas identifies HOXC10 as a key mediator of invasion. Cancer Res, 67, 10163–10172.
98.
ZhangW, HeW, ShiY, et al. (2016a). High expression of KIF20A is associated with poor overall survival and tumor progression in early-stage cervical squamous cell carcinoma. PLoS One, 11, e0167449.
99.
ZhangR, ShenC, ZhaoL, et al. (2016b). Dysregulation of host cellular genes targeted by human papillomavirus (HPV) integration contributes to HPV-related cervical carcinogenesis. Int J Cancer, 138, 1163–1174.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
